Table 2 Best response, PFS and OS according to neutropenia grade.

From: Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer

 

All patients (N = 115)

Neutropenia

 < 3 (N = 89)

Neutropenia

 ≥ 3 (N = 26)

p

PR

44 (38.3%)

29 (32.6%)

15 (57.7%)

0.06

SD

30 (26.1%)

23 (25.8%)

7 (26.9%)

DCR (PR + SD)

74 (64.3%)

52 (58.4%)

22 (84.6%)

PD

32 (27.8%)

29 (32.6%)

3 (11.5%)

NE

9 (7.8%)

8 (9%)

1 (3.8%)

PFS

M-months

6

6

7

0.08

(95% IC)

(5–7)

(5–6)

(5–8)

 

OS

M-months

11

10

13

0.04

95% IC

(9–13)

(8–13)

(10–18)

 

Cycles

Median

5

4

6

0.9

Range

1–17

1–17

1–17

 

GCF-prophylaxis

25 (21.9%)

11 (12.5%)

14 (53.8%)

0.01

  1. Bold values are statistically significant.
  2. N Number, PR partial response, SD stable disease, DCR disease control rate, PD progression disease, NE not evaluable, median Median, PFS progression free survival, OS overall survival.
Back to article page